July 9, 2026

Impact Framework: A Finance-First Perspective on Institutional Capital and Social Impact

A Candid Note on Impact Intentionality

Where Chicago Atlantic’s Cannabis Lending Strategy sits on the impact spectrum

Impact investing exists on a continuum. At one end are ‘impact-first’ strategies that accept concessionary returns in exchange for measurable, ex-ante social outcomes. At the other are conventional, return-only strategies where social outcomes, if any, are purely incidental.

Chicago Atlantic’s cannabis lending strategy sits closer to the finance-first end of this spectrum. Its stated objective is to seek attractive risk-adjusted returns through primarily senior secured lending to state-licensed cannabis operators.

While each investment is evaluated under Chicago Atlantic’s ESG policy as part of the underwriting process, the strategy is not managed to achieve predetermined social outcomes, accept lower returns in pursuit of impact objectives, or provide formal impact reporting. We believe it would be misleading to characterize our cannabis lending strategy as an impact strategy in the strict definitional sense.

What we do assert—with conviction—is that the act of providing institutional capital to the legal, regulated cannabis sector generates material, second-order social outcomes that are durable, observable, and aligned with the priorities of impact-oriented allocators. The case for those outcomes is set out below.

Industry-Level Impact Thesis

The U.S. state-legal cannabis industry is itself an outgrowth of decades of social reform. Its existence is the legislative and regulatory consequence of decades of advocacy around criminal justice, racial equity, medical access, and public health. Capital that supports the viability of the legal market is, by extension, capital that helps sustain—and further—the reform objectives that made the industry possible.

Financial Inclusion: Capital for an Underserved Sector

Conventional banks do not lend to U.S. cannabis businesses, largely due to federal scheduling and banking regulatory risk. This is structural, not credit driven. The businesses Chicago Atlantic lends to are state-licensed, cash-flowing, and frequently collateral-rich—yet they are systematically denied access to conventional capital markets. Providing dependable credit to legally operating businesses that are locked out of conventional finance is a financial inclusion argument with genuine social consequence — analogous to the rationale behind Community Development Financial Institution (CDFI) lending and Minority Depository Institution (MDI) support programs.

Criminal Justice Reform Alignment

The War on Drugs produced well-documented disparities in enforcement and economic opportunity. The transition to a regulated cannabis market represents one policy response to that history. Successful state-licensed operators help advance a legal, transparent, and accountable industry that has replaced prohibition in many jurisdictions.

The scale and persistence of racial disparity in cannabis enforcement are well-documented. The ACLU’s 2020 report, A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform, analyzed FBI arrest data across all 50 states and found:

Black Americans are 3.64 times more likely to be arrested for marijuana possession than white Americans, despite near-identical rates of use across racial groups.
This disparity exists in every single state and in over 96% of counties examined — it is not a regional phenomenon.
In 10 states, Black people were more than 5x more likely to be arrested. In Montana and Kentucky, the disparity exceeded 9x.
Despite legalization expanding across the country, racial disparities in marijuana arrests worsened in 31 states between 2010 and 2018.
Black Americans represent approximately 38.8% of all marijuana possession arrests, despite comprising 13.6% of the U.S. population. In New York City, people of color accounted for 94% of marijuana arrests in 2020.

The persistence of these disparities throughout the legalization era underscores that the regulated cannabis market represents more than the commercialization of a formerly prohibited product. It is an important component of a broader legislative and regulatory effort to address decades of disproportionate enforcement. For that framework to succeed, licensed operators require access to stable, institutional sources of capital.

Our view is that when legal operators are adequately capitalized and able to compete effectively, they displace the illicit market. When they fail for lack of capital, the illicit market fills the void — along with its associated harms, including unregulated product safety, youth access, and criminal activity. Providing capital to keep licensed operators financially viable is, in this sense, a harm reduction activity.

Chicago Atlantic’s Support of Social Equity Initiatives

The firm’s commitment to the regulated cannabis industry extends beyond providing credit to licensed operators. Chicago Atlantic committed approximately $30 million to New York’s Cannabis Social Equity Investment Fund, a public-private initiative established to finance the construction and build-out of dispensaries awarded to individuals disproportionately impacted by the War on Drugs.

One of the principal challenges confronting social equity licensees is not obtaining a license — it is obtaining the capital necessary to build, open, and operate a compliant dispensary. The New York Social Equity Investment Fund was created specifically to address that financing gap by providing capital to support the development of licensed retail locations throughout the state.

Chicago Atlantic’s investment helped support the construction of 23 dispensaries across New York. While this investment was made separately from our cannabis lending strategies, we believe it reflects the firm’s broader commitment to supporting the successful implementation of state social equity programs where institutional capital can play a constructive role.

This investment illustrates an important principle underlying our broader impact thesis: access to institutional capital is often the critical factor determining whether public policy objectives can be translated into durable economic outcomes.

See Governor Hochul Announces $150 Million Investment in the Cannabis Social Equity Investment Fund, New York State Website, May 2023. (Link)

Medical Patient Access

The provision of capital to medical cannabis operators comprises a meaningful portion of Chicago Atlantic’s cannabis lending strategy. Medical cannabis provides clinically recognized, legal access to treatment for chronic pain, PTSD, epilepsy, multiple sclerosis, and other conditions where conventional pharmaceutical options are frequently considered inadequate, unavailable, or carry significant adverse effects. Capital that enables these operators to remain liquid and expand capacity supports patient access to treatment — an outcome with clear social value.

Two landmark federal actions underscore the medical legitimacy of cannabis in ways that are directly relevant to this discussion:

Epidiolex — First FDA-Approved Cannabis-Derived Drug. In June 2018, the FDA approved Epidiolex (cannabidiol, derived directly from the cannabis plant) for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome — rare, catastrophic, treatment-resistant forms of epilepsy with onset in early childhood. This was the first time the FDA had ever approved a drug derived from the cannabis plant, establishing through the agency’s own gold-standard review process that cannabis-derived compounds possess genuine, measurable therapeutic value for some of the most vulnerable patients — children with severe, life-threatening seizure disorders.
FDA/HHS Recommendation to Reschedule Cannabis. In August 2023, the U.S. Department of Health and Human Services formally recommended to the DEA that cannabis be rescheduled from Schedule I to Schedule III. The recommendation was driven by FDA’s scientific review and included an explicit finding that cannabis has a currently accepted medical use in the United States — directly contradicting the Schedule I classification, which by statute requires ‘no accepted medical use.’ The FDA found credible scientific support for cannabis in treating pain, anorexia related to certain conditions, and chemotherapy-induced nausea and vomiting. The agency noted that more than 30,000 licensed healthcare practitioners across 43 U.S. jurisdictions are authorized to recommend medical cannabis to more than 6 million registered patients for at least 15 distinct medical conditions. Critically, the FDA also found that cannabis does not meet the threshold for high abuse potential that defines Schedule I and II substances — effectively repudiating over 50 years of federal scheduling policy. This finding directly enabled the April 2026 DOJ reclassification of medical-use cannabis to Schedule III.

Sources: FDA Drug Approval for Epidiolex (June 2018); HHS/FDA Recommendation to DEA (August 2023); Federal Register, Schedules of Controlled Substances: Rescheduling of FDA-Approved Products Containing Marijuana (April 2026).

Portfolio-Level Impact Characteristics

The following impact-relevant characteristics are observable within Chicago Atlantic’s existing cannabis-focused portfolios and the markets in which they operate.

Social Equity Licensing — State Markets

Several of the states in which the strategy is active have explicit social equity licensing provisions embedded in statute. Illinois, Ohio, Minnesota, and Missouri each incorporate equity applicant criteria — including priority licensing for BIPOC owners, residents of economically disadvantaged communities, and individuals with prior cannabis convictions. Capital deployed in these markets directly or indirectly supports businesses operating within state social equity frameworks.

Regulated vs. Illicit Market Dynamics

While it has been motivated primarily by favorable economic conditions, Chicago Atlantic’s focus on limited-license states is particularly relevant from a harm reduction standpoint. Limited-license markets have fewer, more established operators, and higher wholesale prices. These conditions, when paired with adequate capital, support product quality and retail access, favor compliant operators and can reduce the economic viability of illicit alternatives.

Capital access is the differentiator; high prices alone don’t reduce illicit market share, and in fact, the price gap is one of the strongest known drivers of illicit demand. Capital that strengthens licensed operators in these markets directly contributes to the market displacement of unregulated supply.

Medical Operator Representation

The strategy has historically reflected meaningful exposure to states with significant medical-only programs (MI, OH, PA). Medical operators are subject to heightened regulatory scrutiny, product testing requirements, and patient safety standards. Their financial stability is a prerequisite for sustained patient access.

Job Creation & Economic Development

The legal cannabis industry supported approximately 445,800 full-time equivalent jobs in 2025—up 5% from 2023—across cultivation (~30%), retail (~23%), processing and packaging (~17%), and ancillary services (~30%). Top employment states include California (~80,900), Michigan (~38,900), Colorado (~32,900), Florida (~32,800), and Illinois (~30,800), closely aligned with the strategy’s historical concentration. Industry projections point to approximately 800,000 jobs by 2029.¹ These are predominantly working-class positions: budtenders earn $31,000–$40,000 per year, entry-level, and do not require a college degree.

In Colorado, approximately 35% of cannabis employees are nonwhite.² In Illinois, approximately 40% of newly issued social equity dispensary licenses have gone to majority Black-owned businesses, and a majority of total licenses are held by minority or women‑owned firms.³

The equity picture is strongest in social equity licensing states. Financing operators in those frameworks is where the most durable socioeconomic impact is concentrated.

Sources:
¹ Leafly Jobs Report / Vangst Cannabis Jobs Report (2025–2026 data)

² Rudick Law Group, “Diversity in the Cannabis Industry: The State of Social Equity in the Cannabis Industry” (February 25, 2025)

³ Office of Governor J.B. Pritzker, “Independent Disparity Study Finds Illinois Has Most Diverse Cannabis Business Ownership,” July 10, 2024

Investment Structure as a Social Enabler

The structural features of the cannabis lending strategy have a direct bearing on its social impact profile — not incidentally, but as a function of how the strategy is designed.

Bank displacement creates impact access. Because mainstream banks avoid lending to this sector, private institutional capital does not merely compete alongside conventional finance — it fills a void. Premium returns may, in part, be generated by providing access that would not otherwise exist. This is the classic ‘additionality’ test in impact investing: the activity would not occur, or would occur on far worse terms, without this capital.
Conservative underwriting supports compliance. The strategy’s ‘zero loss’ underwriting discipline — senior secured positions, low LTVs, robust covenants, and focus on cash-flowing operators — means capital is directed to the most operationally sound, compliant operators in the market. Chicago Atlantic does not finance speculative, pre-revenue, or construction-stage businesses. Supporting established operators reinforces the legitimacy and stability of the regulated market.
Monthly reporting requirements improve operator governance. Chicago Atlantic’s covenant and reporting structures — monthly financial reporting, Debt Service Coverage Ratio (DSCR) covenants, cash management controls — impose governance discipline on borrowers that goes beyond state licensing requirements. This has a positive spillover effect on the professionalism and sustainability of the operators Chicago Atlantic supports.
Federal rescheduling as a structural impact catalyst. The April 2026 DOJ reclassification of medical cannabis from Schedule I to Schedule III eliminates the punitive 280E tax burden for medical operators and appears to signal a broader normalization of the regulated market. As the legal framework strengthens, the social infrastructure built around state-licensed cannabis — jobs, medical access, equity programs, tax revenues — becomes more durable and less vulnerable to reversal.

Acknowledgment of Current Limitations

We believe in presenting this framework with the same transparency we apply to our credit underwriting. The following limitations should be acknowledged by any allocator evaluating the cannabis lending strategy through a formal impact lens.

No ex-ante impact targets. Chicago Atlantic does not select borrowers to achieve predefined social outcomes, establish quantitative impact objectives, or accept concessionary returns in exchange for social impact. This distinction should not be construed to mean that ESG considerations are disregarded. Rather, prospective investments are evaluated under the firm’s ESG policy during underwriting. Our investment objective is to generate attractive risk-adjusted financial returns. Any measurable social impact arises as a consequence of pursuing that objective, rather than as an independent investment objective.
No formal impact measurement or reporting framework. Chicago Atlantic does not currently produce impact reports aligned with IRIS+, HIPSO, or the UN Sustainable Development Goals (SDGs). Investors seeking standardized impact reporting are encouraged to discuss their reporting requirements with Chicago Atlantic to evaluate the feasibility of developing appropriate impact metrics.
Environmental considerations. The environmental profile of cannabis cultivation varies materially by method. Indoor cultivation is energy-intensive — artificial lighting, HVAC, and climate control create a meaningful carbon footprint. Outdoor cultivation, by contrast, has a comparatively favorable environmental profile: it requires minimal water relative to most row crops, does not demand re-tilling or soil disruption between grows, and carries low risk of soil degradation. Cannabis has also been studied as a phytoremediation crop capable of drawing contaminants out of soil. Chicago Atlantic does not screen for cultivation method or environmental performance and does not produce environmental impact reporting. Allocators with formal environmental screens should evaluate this accordingly.
Cannabis remains federally controlled. Medical cannabis was reclassified from Schedule I to Schedule III by the DEA in April 2026 — a meaningful shift that eliminates the 280E tax penalty for medical operators and signals that federal policy is, for the first time, tracking the scientific and medical consensus on cannabis. Adult-use cannabis remains Schedule I. The rescheduling of medical use is a concrete data point in a trajectory of regulatory normalization and may portend continued progress on the adult-use side. Allocators whose investment policy statements exclude Schedule I or controlled substance exposure should evaluate their specific mandate against this evolving landscape.

Summary

Chicago Atlantic’s cannabis lending strategy is a finance-first approach to private credit. It is not an impact strategy, and we would not represent it as such. What it is: a senior secured credit strategy that directs institutional capital toward a legally operating, underserved sector whose social significance — as a direct consequence of criminal justice reform, medical access policy, and harm reduction — is difficult to overstate. The second-order impact of keeping the legal, regulated cannabis market well-capitalized, compliant, and financially viable is real, observable, and aligned with the priorities of allocators who manage capital with social consciousness. For allocators who require formal impact intentionality, we welcome a direct conversation about whether impact measurement and reporting frameworks could be developed as a complement to the existing strategy.

This document is provided for informational purposes only. All investments involve risk, including the risk of loss.

For important information about this content, refer to DISCLOSURES & IMPORTANT INFORMATION.